Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-A3 Immunizations With Hiltonol Plus T Cells and Lenalidomide After ASCT for Advanced Myeloma
NCT01245673Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- May 2011
- Primary completion
- Dec 2015
- Modality
- Prophylactic Vaccines, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of MAGE-A3 vaccine in multiple myeloma (MM), sponsored by University of Pennsylvania. Started May 2011; status: completed.
02
Drugs
MAGE-A3 vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01245673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245673.